The First Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of an FcRn Inhibitor, Rozanolixizumab, in Patients With Leucine-Rich Gliomainactivated 1 Autoimmune Encephalitis.

Details

Language :

English

ISSN :

00283878

Volume :

99

Database :

Complementary Index

Journal :

Neurology

Publication Type :

Academic Journal

Accession number :

160730213

Full Text :

https://doi.org/10.1212/01.wnl.0000903336.22071.b3